[go: up one dir, main page]

MD4531B1 - Derivaţi ai benzimidazolonei în calitate de inhibitori ai bromodomeniului - Google Patents

Derivaţi ai benzimidazolonei în calitate de inhibitori ai bromodomeniului Download PDF

Info

Publication number
MD4531B1
MD4531B1 MDA20150104A MD20150104A MD4531B1 MD 4531 B1 MD4531 B1 MD 4531B1 MD A20150104 A MDA20150104 A MD A20150104A MD 20150104 A MD20150104 A MD 20150104A MD 4531 B1 MD4531 B1 MD 4531B1
Authority
MD
Moldova
Prior art keywords
bromodomain inhibitors
compounds
benzimidazolone derivatives
bromodomain
inhibitors
Prior art date
Application number
MDA20150104A
Other languages
English (en)
Russian (ru)
Other versions
MD4531C1 (ro
MD20150104A2 (ro
Inventor
Евангелос АКТОУДИАНАКИС
Грегори ЧИНЬ
Бриттон Кеннет Корки
Цзиньфа Ду
Кристина Элбел
Роберт Х. Цзян
Тецуя Кобаяси
Рубен Мартинес
Сэмюель Е. МЕТОБО
Майкл Миш
Софи Шевик
Дэвид Сперандио
Х Ян
Джефф ЗАБЛОКИ
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of MD20150104A2 publication Critical patent/MD20150104A2/ro
Publication of MD4531B1 publication Critical patent/MD4531B1/ro
Publication of MD4531C1 publication Critical patent/MD4531C1/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Invenţia se referă la compuşi chimici care pot acţiona ca inhibitori sau care în alt mod pot modula activitatea unei proteine conţinând un domeniu bromic, inclusiv a proteinei conţinând domeniul bromic 4 (BRD4), la compoziţii şi formulări ce conţin astfel de compuşi, precum şi la utilizarea unor astfel de compuşi. Compuşii sunt prezentaţi de formula (I)(I),în care semnificaţiile R1a, R1b, R2a, R2b, R3 şi X sunt dezvăluite în descriere şi revendicări.
MDA20150104A 2013-03-28 2014-03-27 Derivaţi ai benzimidazolonei în calitate de inhibitori ai bromodomeniului MD4531C1 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361805995P 2013-03-28 2013-03-28
US201361860230P 2013-07-30 2013-07-30
PCT/US2014/032031 WO2014160873A1 (en) 2013-03-28 2014-03-27 Benzimidazolone derivatives as bromodomain inhibitors

Publications (3)

Publication Number Publication Date
MD20150104A2 MD20150104A2 (ro) 2016-02-29
MD4531B1 true MD4531B1 (ro) 2017-11-30
MD4531C1 MD4531C1 (ro) 2018-06-30

Family

ID=50897885

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150104A MD4531C1 (ro) 2013-03-28 2014-03-27 Derivaţi ai benzimidazolonei în calitate de inhibitori ai bromodomeniului

Country Status (35)

Country Link
US (2) US20160031868A1 (ro)
EP (1) EP2978759B1 (ro)
JP (1) JP6339175B2 (ro)
KR (1) KR101847698B1 (ro)
CN (1) CN105102453B (ro)
AP (1) AP2015008741A0 (ro)
AU (1) AU2014241152B2 (ro)
BR (1) BR112015024078A2 (ro)
CA (1) CA2907502C (ro)
CL (1) CL2015002871A1 (ro)
CR (1) CR20150515A (ro)
CY (1) CY1119165T1 (ro)
DK (1) DK2978759T3 (ro)
EA (1) EA029497B1 (ro)
ES (1) ES2626397T3 (ro)
HR (1) HRP20170750T1 (ro)
HU (1) HUE034772T2 (ro)
IL (1) IL241186A0 (ro)
LT (1) LT2978759T (ro)
MD (1) MD4531C1 (ro)
MX (1) MX2015013798A (ro)
MY (1) MY176634A (ro)
NZ (1) NZ711586A (ro)
PE (1) PE20151982A1 (ro)
PH (1) PH12015502246A1 (ro)
PL (1) PL2978759T3 (ro)
PT (1) PT2978759T (ro)
RS (1) RS56050B1 (ro)
SG (1) SG11201507926RA (ro)
SI (1) SI2978759T1 (ro)
SM (1) SMT201700249T1 (ro)
TW (1) TWI530499B (ro)
UY (1) UY35516A (ro)
WO (1) WO2014160873A1 (ro)
ZA (1) ZA201506356B (ro)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
WO2010106436A2 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Novel anti-inflammatory agents
TR201909777T4 (tr) 2011-11-01 2019-07-22 Resverlogix Corp Sübsti̇tüe ki̇nazoli̇nonlara yöneli̇k oral çabuk salimli formülasyonlar
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2014143768A1 (en) 2013-03-15 2014-09-18 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
WO2015004534A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
JP6461121B2 (ja) * 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． 新規の二環式ブロモドメイン阻害剤
ES2635560T3 (es) 2013-07-08 2017-10-04 Incyte Holdings Corporation Heterociclos tricíclicos como inhibidores de la proteína NET
CN105593224B (zh) 2013-07-31 2021-05-25 恒元生物医药科技(苏州)有限公司 作为溴结构域抑制剂的新型喹唑啉酮类化合物
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
ES2942723T3 (es) 2014-04-23 2023-06-06 Incyte Holdings Corp 1H-pirrolo[2,3-C]piridin-7(6H)-onas y pirazolo[3,4-C]piridin-7(6H)-onas como inhibidores de proteínas BET
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
CN107108512B (zh) * 2014-10-10 2021-05-04 基因泰克公司 治疗性化合物及其用途
EP3206749B1 (en) 2014-10-14 2021-09-08 The Regents of the University of California The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
CN107406438B (zh) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
GB201504689D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
EP3397640B1 (en) 2015-12-29 2021-08-04 INSERM - Institut National de la Santé et de la Recherche Médicale Xanthine derivative inhibitors of bet proteins
KR20250163425A (ko) 2016-06-20 2025-11-20 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
US20180179191A1 (en) * 2016-11-22 2018-06-28 Gilead Sciences, Inc. Synthesis of a compound that modulates the activity of bromodomain-containing proteins
EP3707139B1 (en) 2017-11-06 2022-02-16 Centre National de la Recherche Scientifique Xanthine derivatives and uses thereof as inhibitors of bromodomains of bet proteins
CA3086054A1 (en) 2017-12-20 2019-06-27 Betta Pharmaceuticals Co., Ltd Compound functioning as bromodomain protein inhibitor, and composition
JP7394140B2 (ja) * 2019-02-02 2023-12-07 シーエスピーシー ゾンチー ファーマシューティカル テクノロジー（シージアチュアン）カンパニー，リミテッド 標的ユビキチン化分解ｂｒｄ４タンパク質化合物、その調製方法および応用
CN109912584B (zh) * 2019-03-22 2021-08-13 中国药科大学 一种具有抗肿瘤活性的brd4蛋白抑制剂及其制备方法和应用
EP4039333A4 (en) 2019-09-30 2024-02-14 Kyowa Kirin Co., Ltd. BET DEGRADATION AGENT
WO2021237111A1 (en) * 2020-05-21 2021-11-25 Stemsynergy Therapeutics, Inc. Notch inhibitors and uses thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN117821344B (zh) * 2024-03-06 2024-07-26 江苏古道农业科技有限公司 一种草甘膦降解菌及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5616345A (en) * 1983-12-22 1997-04-01 Elan Corporation Plc Controlled absorption diltiazen formulation for once-daily administration
WO2013024104A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
BRPI0814939A2 (pt) 2007-08-10 2015-01-27 Glaxosmithkline Llc Entidade química, composição farmacêutica, e, método para tratar uma infecção viral em um mamífero.
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
ES2786298T3 (es) 2011-03-03 2020-10-09 Zalicus Pharmaceuticals Ltd Inhibidores de benzimidazol del canal de sodio
JP6461121B2 (ja) * 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． 新規の二環式ブロモドメイン阻害剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5616345A (en) * 1983-12-22 1997-04-01 Elan Corporation Plc Controlled absorption diltiazen formulation for once-daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
WO2013024104A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
Berge S. M. et al., J. Pharma Sci., 66(1), 1-19 (1977) *
BET inhibitor. WikipediA, The Free Encyclopedia. Regăsit în Internet la 2017.04.27, url: https://en.wikipedia.org/wiki/BET_inhibitor *
Brooks, W. H., et al., J. Autoimmun., 34: J207-219 (2010) *
Chung, C. W., et al., J. Med. Chem., 54: 3827-3838 (2011) *
Cohen, I., et al., Genes Cancer, 2: 631-647 (2011) *
Delmore, J. E., et al. Cell, 146, 904-917 (2011) *
Filippakopoulos, P., et al. Cell, 149: 214-231 (2012) *
Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci., 5(12):524-527 (1984) *
Iang, Z., et al. Mol. Cell Biol., 28: 967-976 (2008) *
J. Org. Chem. 1995, 60, 3781-3786 *
Loven, J. et al., Cell, 153, 320-334 (2013) *
Muller, S., et al., Expert Rev. Mol. Med., 13: 401-409 (2011) *
Remington: The Sciense and Practice of Pharmacy, R. Hendrickson editor, 21st edition, Lippincott, Williams & Wilkins, Philadelphia, PA, (2005), la pag. 732, Tabelul 38-5 *
Shi Junwei, C.R. Vakoc. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell. 2014 June 5; 54(5): 728-736. DOI: 10.1016/j.molvel.2014.05.016. Regăsit în Internet la 2017.09.07, url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236231/ *
Shirodkar, A.V. and Marsden, P.A., Curr. Opin. Cardiol., 26: 209-215 (2011) *
Urano, E., et al., FEBS Lett., 582: 405-408 (2008) *
Villeneuve, L.M., etal., Clin. Exp. Pharmacol. Physiol., 38: 401-409 (2011) *
Wierda, R. J., et al., J. Cell Mol. Med., 14: 1225-1240 (2010) *
Wu, S.I., Chiang, C.M. J. Biol. Chem., 282: 13141-13145 (2007) *
Zhou, M., et al., J. Virol., 83: 1036-1044 (2009) *

Also Published As

Publication number Publication date
UY35516A (es) 2014-09-30
CY1119165T1 (el) 2018-02-14
CL2015002871A1 (es) 2016-05-13
ZA201506356B (en) 2017-08-30
CR20150515A (es) 2015-12-01
SMT201700249T1 (it) 2017-07-18
CN105102453A (zh) 2015-11-25
AP2015008741A0 (en) 2015-09-30
CA2907502A1 (en) 2014-10-02
PE20151982A1 (es) 2016-01-28
EP2978759B1 (en) 2017-03-15
TW201504233A (zh) 2015-02-01
HUE034772T2 (en) 2018-02-28
US20140296246A1 (en) 2014-10-02
MD4531C1 (ro) 2018-06-30
RS56050B1 (sr) 2017-09-29
NZ711586A (en) 2016-09-30
PT2978759T (pt) 2017-05-31
HRP20170750T1 (hr) 2017-07-28
LT2978759T (lt) 2017-05-25
EP2978759A1 (en) 2016-02-03
BR112015024078A2 (pt) 2017-07-18
CN105102453B (zh) 2018-04-06
DK2978759T3 (da) 2017-06-19
CA2907502C (en) 2018-02-27
WO2014160873A1 (en) 2014-10-02
SG11201507926RA (en) 2015-10-29
AU2014241152B2 (en) 2016-11-03
EA201591455A1 (ru) 2016-01-29
MY176634A (en) 2020-08-19
ES2626397T3 (es) 2017-07-24
TWI530499B (zh) 2016-04-21
JP6339175B2 (ja) 2018-06-06
KR20150135476A (ko) 2015-12-02
US20160031868A1 (en) 2016-02-04
SI2978759T1 (sl) 2017-05-31
HK1220692A1 (en) 2017-05-12
PH12015502246A1 (en) 2016-02-01
PL2978759T3 (pl) 2017-08-31
US9255089B2 (en) 2016-02-09
EA029497B1 (ru) 2018-04-30
IL241186A0 (en) 2015-11-30
AU2014241152A1 (en) 2015-09-17
JP2016515584A (ja) 2016-05-30
KR101847698B1 (ko) 2018-04-10
MD20150104A2 (ro) 2016-02-29
MX2015013798A (es) 2016-02-16

Similar Documents

Publication Publication Date Title
MD4531B1 (ro) Derivaţi ai benzimidazolonei în calitate de inhibitori ai bromodomeniului
PH12015502534A1 (en) Benzimidazole derivatives as bromodomain inhibitors
MA32508B1 (fr) Composes organiques
MX2015011097A (es) Inhibidores de histona desmetilasas.
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
IN2015MN00405A (ro)
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
UA116467C2 (uk) Модулятори p2x7
MX2016008110A (es) Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
MX356342B (es) Agente de control de endoparásitos y método para usarlo.
NZ729618A (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
CR20140135A (es) Nuevos derivados de aril-quinolina
CR20160171A (es) NUEVO OCTAHIDRO-CICLOBUTA[1,2-c; 3,4-c] DIPIRROL-2-ILO
MX390051B (es) Antagonistas de ep4.
MX2018001317A (es) Inhibidores del virus sincitial respiratorio.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
UA115583C2 (uk) Азетидинілоксифенілпіролідинові сполуки
NZ719465A (en) Quinoline derivatives as bromodomain inhibitors
MX368635B (es) Compuestos tricíclicos de piperidina.
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2015010790A (es) Derivados de anilina sustituidos con n-heteroarilo como antivirales de vhc.
UA110131C2 (ru) ПРОИЗВОДНЫЕ ТИЕНО[2,3-d]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АРИТМИИ
PH12015500292A1 (en) 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel
UA111315C2 (uk) Похідні бензімідазолону як інгібітори бромодомену

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees